Innova Captab IPO: Soaring Demand! Over 22 Times Subscribed on Day 3; NII, Retail Portions Oversubscribed. GMP Takes a Dip

Innova Captab IPO Witnesses Phenomenal Demand on Day 3 of Subscription, Driven by Overwhelming Response from Non-Institutional Investors (NII) and Retail Participants.

Innova Captab IPO Subscription Update: Phenomenal Response as Non-Institutional Investors (NII) and Retail Investors Drive Subscriptions on Day 3. The current subscription status stands at an impressive 22.34 times.

Notably, the IPO was fully subscribed on the second day, with an overall positive response from investors. The subscription status on day 2 reached 3.54 times, indicating strong investor interest.

The price band for Innova Captab IPO is established between ₹426 to ₹448 per equity share with a face value of ₹10. The floor price represents 42.60 times the face value, while the cap price is 44.80 times the face value of the equity shares. Evaluating the price to earnings ratio based on diluted EPS for fiscal 2023, it stands at 30.08 times at the floor price and 31.64 times at the cap price. The lot size for Innova Captab IPO is set at 33 equity shares, with multiples available thereafter in sets of 33 equity shares.

About The Company

An integrated pharmaceutical company based in India operates across the entire pharmaceutical value chain, encompassing research and development, manufacturing, drug distribution, marketing, and global exports.

Established in 2006, the company has witnessed substantial growth over the past 15 years, catering to prominent Indian pharmaceutical companies, including 10 of the top 10 and 14 of the top 15 players in the industry. Holding licenses for two state-of-the-art manufacturing facilities, the company adheres to stringent quality standards such as WHO-GMP, EU-GMP, and other major registrations, ensuring the production of high-quality pharmaceutical products.

At the core of the company’s operations lies its in-house research and development (R&D) division. This strategic emphasis enables the company to curate a diverse and sophisticated product portfolio, attracting and retaining a broad customer base. The company boasts a robust team of over 1000 employees, contributing to its ongoing success.

Demonstrating a commitment to corporate responsibility, the company consistently complies with Environmental, Social & Governance (ESG) standards. This commitment spans legal compliance, ethical business conduct, quality and patient safety, human rights, labor and employment standards, employee health and safety, sustainability, and environmental responsibility.

Leave a comment